Comparison of Immunogenicity and Reactogenicity of Inactivated Sars-Cov Vaccine (Coronavac) in Previously Sars-Cov Infected and Uninfected Health Care Workers

dc.authorid Karabayir, Nalan/0000-0002-8003-1952
dc.authorid Gonullu, Erdem/0000-0002-6833-5646
dc.authorid Yildiz, Ismail/0000-0003-3570-8394
dc.authorid Karabocuoglu, Metin/0000-0003-2854-0562
dc.authorid Alan, Servet/0000-0002-8228-6350
dc.authorwosid Karabayir, Nalan/Cai-5483-2022
dc.authorwosid Atici, Serkan/Iuo-9237-2023
dc.authorwosid Gonullu, Erdem/C-7080-2019
dc.authorwosid Yildiz, Ismail/Iys-3768-2023
dc.contributor.author Soysal, Ahmet
dc.contributor.author Gonullu, Erdem
dc.contributor.author Karabayir, Nalan
dc.contributor.author Alan, Servet
dc.contributor.author Atici, Serkan
dc.contributor.author Yildiz, Ismail
dc.contributor.author Karabocuoglu, Metin
dc.date.accessioned 2024-05-25T12:34:13Z
dc.date.available 2024-05-25T12:34:13Z
dc.date.issued 2021
dc.department Okan University en_US
dc.department-temp [Soysal, Ahmet; Karabocuoglu, Metin] Mem Atasehir Hosp, Clin Pediat, Vedat Gunyol St 28, TR-34758 Istanbul, Turkey; [Gonullu, Erdem] Istanbul Hlth & Technol Univ, Dept Pediat, Istanbul, Turkey; [Karabayir, Nalan] Medipol Univ Hosp, Dept Pediat, Istanbul, Turkey; [Alan, Servet] Mem Sisli Hosp, Clin Infect Dis, Istanbul, Turkey; [Atici, Serkan] Okan Univ Hosp, Dept Pediat Infect Dis, Istanbul, Turkey; [Yildiz, Ismail] Namik Kemal Univ, Dept Pediat, Sch Med, Tekirdag, Turkey; [Engin, Havva] Mem Atasehir Hosp, Hosp Infect Control Unit, Istanbul, Turkey; [civilibal, Mahmut] Mem Bahcelievler Hosp, Dept Pediat, Istanbul, Turkey en_US
dc.description Karabayir, Nalan/0000-0002-8003-1952; Gonullu, Erdem/0000-0002-6833-5646; Yildiz, Ismail/0000-0003-3570-8394; Karabocuoglu, Metin/0000-0003-2854-0562; Alan, Servet/0000-0002-8228-6350 en_US
dc.description.abstract The effects of inactivated SARS-CoV-2 vaccine (CoronaVac) on previously naturally infected individuals are unknown. This study compared immunogenicity and reactogenicity of CoronaVac in once naturally infected health-care workers (HCWs) and uninfected HCWs. All HCWs were immunized with two doses of CoronaVac (600 U/0.5 ml) intramuscularly at a 28-day interval. Adverse reactions were obtained by web-based questionnaires or telephone calls seven days after each vaccine dose. Detection of antibody levels against the receptor-binding domain (RBD) of SARS-CoV-2 spike protein was done four weeks after the second dose of the vaccine. We enrolled 103 previously naturally infected and 627 uninfected HCWs. The mean time for vaccination after the first nasopharyngeal SARS-CoV-2 positivity was 64 days (range: 15-136 days) in previously naturally infected HCWs. Among the previously naturally infected HCWs, 41 (40%) were asymptomatic, 52 (50%) had mild upper respiratory tract infections, 10 (105) had pneumonia, and only 6 (5%) were hospitalized. Any reported adverse reactions, either from the first dose or the second dose of vaccine administration, did not differ between previously infected and uninfected HCWs. Anti-RBD antibody titers were obtained in 50 (51%) of 103 previously infected HCWs and 142 (23%) of 627 uninfected HCWs. Anti-RBD antibody titers were significantly higher in HCWs with a previous natural infection (median 1220 AU/ml, range: 202-10328 AU/mL) than in uninfected HCWs (median: 913 AU/ml, range: 2.8-15547 AU/mL, p = .032). CoronaVac administration was safe and may elicit higher antibody responses in previously naturally infected individuals. en_US
dc.description.woscitationindex Science Citation Index Expanded
dc.identifier.citationcount 17
dc.identifier.doi 10.1080/21645515.2021.1953344
dc.identifier.endpage 3880 en_US
dc.identifier.issn 2164-5515
dc.identifier.issn 2164-554X
dc.identifier.issue 11 en_US
dc.identifier.pmid 34324409
dc.identifier.scopus 2-s2.0-85111796073
dc.identifier.scopusquality Q2
dc.identifier.startpage 3876 en_US
dc.identifier.uri https://doi.org/10.1080/21645515.2021.1953344
dc.identifier.volume 17 en_US
dc.identifier.wos WOS:000679215500001
dc.identifier.wosquality Q1
dc.language.iso en
dc.language.iso en en_US
dc.publisher Taylor & Francis inc en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.scopus.citedbyCount 19
dc.subject Sars-Cov-2 Inactivated Virus Vaccine en_US
dc.subject Coronavac en_US
dc.subject Health Care Workers en_US
dc.subject Vaccine Antibody Response en_US
dc.subject Vaccine Adverse Effects en_US
dc.subject Turkey en_US
dc.title Comparison of Immunogenicity and Reactogenicity of Inactivated Sars-Cov Vaccine (Coronavac) in Previously Sars-Cov Infected and Uninfected Health Care Workers en_US
dc.type Article en_US

Files